市場調查報告書

CRISPR、Cas遺傳基因群的市場規模:市場佔有率、趨勢分析,各產品及服務(媒介為基礎的Cas,無DNA Cas,細胞株工程),各用途,各最終用途,及市場區隔預測(2020年∼2027年)

CRISPR & Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Vector-basedCas, DNA-freeCas, Cell Line Engineering), By Application, By End Use, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 940842
出版日期 內容資訊 英文 212 Pages
商品交期: 2-3個工作天內
價格
CRISPR、Cas遺傳基因群的市場規模:市場佔有率、趨勢分析,各產品及服務(媒介為基礎的Cas,無DNA Cas,細胞株工程),各用途,各最終用途,及市場區隔預測(2020年∼2027年) CRISPR & Cas Genes Market Size, Share & Trends Analysis Report By Product & Service (Vector-basedCas, DNA-freeCas, Cell Line Engineering), By Application, By End Use, And Segment Forecasts, 2020 - 2027
出版日期: 2020年05月28日內容資訊: 英文 212 Pages
簡介

全球CRISPR、Cas遺傳基因群的市場規模,預計從2020年到2027年之間以16.6%的年複合成長率擴大,2027年達到48億8,000萬美元。該市場的主要成長要素,是表觀遺傳學,治療學,人生殖細胞編輯,植物基因編輯,及其他的生物科技領域的CRISPR技術的採用增加。

本報告提供全球CRISPR、Cas遺傳基因群市場的相關調查,市場機會和趨勢,成長及阻礙因素,各產品及服務、用途、最終用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查手法

第2章 摘要整理

第3章 市場變數,趨勢及規模

  • 市場趨勢與展望
  • 市場區隔和範圍
  • 市場系預測
  • 專利形勢
  • 各生物醫學用途:滲透與成長預測製圖
  • 對Crispr技術的潛在威脅分析
  • 投資者的觀點分析
  • 用戶的觀點分析
  • Crispr基因編輯工作流程的科技製圖
  • 偏離目標效果分析的開發與革新
  • 臨床的滲透

第4章 產業的展望

  • 市場動態
    • 市場成長要素分析
    • 阻礙市場要素分析
    • 市場機會分析
    • 市場課題分析
  • 使用了Crispr的基因改造的政策作成與法規
  • 波特的五力分析
  • SWOT分析(政治及法律,經濟,技術)

第5章 競爭情形

  • 活用了遺傳基因編輯技術的企業(診斷及醫藥品開發商)
  • 主要交易與策略性聯盟分析
  • 打入市場策略
  • 開發平台分析

第6章 市場分析:各產品和服務

  • 市場趨勢分析
  • 各產品
  • 各類服務

第7章 市場分析:各用途

  • 市場趨勢分析
  • 生物醫學
  • 農業

第8章 市場分析:各最終用途

  • 市場趨勢分析

第9章 市場分析:各地區

  • 市場趨勢分析2027
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲(Mea)

第10章 企業簡介

  • 主要創新者及關注的研究
  • 策略架構
  • 市場參與企業的分類
  • 企業簡介
目錄
Product Code: GVR-1-68038-375-1

CRISPR & Cas Genes Market Growth & Trends

The global clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes market size is expected to reach USD 4.88 billion by 2027, expanding at a CAGR of 16.6% from 2020 to 2027, according to a new report by Grand View Research, Inc. Rise in the adoption of CRISPR technology in epigenetics, therapeutics, human germline editing, plant genome editing, and other fields of biotechnology is expected to drive the market.

Presence of a large number of service providers that provide knockout, knock-in, gene repression, gene activation, and other cell line engineering services propel the growth of cell line engineering services. In biomedical applications, genome engineering held the largest revenue share in 2019. Adoption of gene editing techniques for human- and non-human-based genomic engineering is one of the key factors that drive the segment.

The molecular scissor can facilitate the detection of viruses, allowing the development of cost-effective, robust, and rapid point-of-care diagnostics. It allows the detection of viruses at a level of molecular concentration that researchers rarely assess. Sherlock Bioscience estimated that a CRISPR-powered diagnostic test would be available in the future at a reasonable price. In recent times, the most important innovation has been the development of a test for COVID-19.

In March 2020, Mesa Biotech announced FDA authorization for its Accula device, a hand-held COVID-19 diagnostic test. Similarly, in April 2020, CSIR lab announced the development of a paper-strip test for Covid-19 that uses CRISPR-Cas9 to target and identifies the genomic sequences of the virus. Unlike the PCR tests, this test is available at a very low price, USD 6.59 (INR 1 = USD 0.013). Therefore, such initiatives are expected to encourage other players to leverage this crisis and launch novel products.

CRISPR & Cas Genes Market Report Highlights

The product segment is anticipated to dominate the market throughout the forecast period. This is attributed to the presence of enhanced individual products that can serve multiple purposes including genome engineering, specific genome cleavage using gRNAs, easy gene knockouts, along with reduced off-target cutting, and increased specificity

Cell line engineering services accounted for the largest market share in 2019. The development of this technology has simplified the genome engineering process to a large extent

In biomedical applications, genome engineering held the largest revenue share in 2019 as a result of an increase in the adoption of genome editing techniques for modifications in germline and therapeutics development

Recent advancements in CRISPR/Cas genome editing allow targeted modification in crops, thereby promising crop improvement and revenue generation in the market

A significant number of research studies carried out to develop disease-specific novel therapies and presence of a huge clinical pipeline that integrates the application of this gene-editing technology are expected to boost revenue generation for the biotechnology and pharmaceutical companies segment

Asia Pacific is anticipated to witness the fastest growth over the forecast period. China holds a significant position in the CRISPR market and is increasingly exploring genome-editing for the development of medicines. The country has launched several CRISPER-based clinical trials, especially for cancer treatment.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information Or Data Analysis
  • 1.3 Market Model
    • 1.3.1 Parent Market Study
    • 1.3.2 Crispr And Cas Genes Market Study
      • 1.3.2.1 Market Study, By Product & Service
      • 1.3.2.2 Market Study, By Application
      • 1.3.2.3 Market Study, By End - Use
      • 1.3.2.4 Market Study, By Region
  • 1.4 Objectives
    • 1.4.1 Objective 1:
    • 1.4.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot, 2019 (USD Million)

Chapter 3 Crispr And Cas Genes Market Variables, Trends & Scope

  • 3.1 Market Trends & Outlook
  • 3.2 Market Segmentation & Scope
  • 3.3 Market Lineage Outlook
    • 3.3.1 Parent Market Outlook
    • 3.3.2 Related/Ancillary Market Outlook
  • 3.4 Crispr And Cas Genes: Patent Landscape
    • 3.4.1 By End - Use Settings
    • 3.4.2 By Variants Of Crispr Enzymes
  • 3.5 Penetration And Growth Prospect Mapping, By Biomedical Applications, 2019
  • 3.6 Potential Threat Analysis To Crispr Technology
    • 3.6.1 Variations In The Crispr System
  • 3.7 Investors Perspective Analysis
  • 3.8 User Perspective Analysis
  • 3.9 Technology Mapping In Crispr Genome Editing Workflow
  • 3.10 Developments And Innovations For Analysis Of Off - Target Effects
  • 3.11 Crispr Technologies: Clinical Penetration
    • 3.11.1 Human Therapeutics
    • 3.11.2 Diagnostics
    • 3.11.3 Microbiome Research And Drug Resistance
    • 3.11.4 Animal Disease Models

Chapter 4 Industry Outlook

  • 4.1 Market Dynamics
    • 4.1.1 Market Driver Analysis
      • 4.1.1.1 Rising Adoption In Diverse Fields Of Biotechnology
      • 4.1.1.1.1 Epigenetics
      • 4.1.1.1.2 Medicine
      • 4.1.1.1.3 Human Germline Editing
      • 4.1.1.1.4 Tool For Qualitative And Quantitative Plant Genome Editing
      • 4.1.1.2 Technological Advancements In Crispr
      • 4.1.1.3 Introduction Of Anti - Crispr Protein
      • 4.1.1.4 Ongoing Competition For Crispr Commercialization
    • 4.1.2 Market Restraint Analysis
      • 4.1.2.1 Off - Target Effects Of Crispr Technology
      • 4.1.2.2 Intellectual Property Disputes Pertaining To Cas
      • 4.1.2.3 Ethical Concerns And Implications With Respect To Human Genome Editing
    • 4.1.3 Market Opportunity Analysis
      • 4.1.3.1 Expanding Gene & Cell Therapy Area
      • 4.1.3.2 Government Fund In Genomic R&D
    • 4.1.4 Market Challenge Analysis
      • 4.1.4.1 Risks Pertaining To The Usage Of Genetically Modified Food
  • 4.2 Policy Making & Regulation For Genetic Modification Using Crispr
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Threat Of New Entrants: Moderate
    • 4.3.2 Competitive Rivalry: High
    • 4.3.3 Threat Of Substitutes: Moderate
    • 4.3.4 Bargaining Power Of Suppliers: Low
    • 4.3.5 Bargaining Power Of Buyers: Moderate
  • 4.4 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
    • 4.4.1 Political & Legal
    • 4.4.2 Economic
    • 4.4.3 Technological

Chapter 5 Competitive Landscape

  • 5.1 Companies (Diagnostic & Drug Developers) Leveraging Gene Editing Technologies
  • 5.2 Major Deals & Strategic Alliances Analysis
  • 5.3 Market Entry Strategies
    • 5.3.1 Crispr Therapeutics: Business Translation
    • 5.3.2 Crispr Gene Editing Companies' Toolboxes
  • 5.4 Crispr And Cas Genes Market: Pipeline Analysis
    • 5.4.1 Editas Medicine
    • 5.4.2 Intellia Therapeutics, Inc.
    • 5.4.3 Crispr Therapeutics
    • 5.4.4 Caribou Biosciences, Inc.
    • 5.4.5 Egenesis
    • 5.4.6 Beam Therapeutics
    • 5.4.7 Ksq Therapeutics
    • 5.4.8 Cibus

Chapter 6 Product & Service Business Analysis

  • 6.1 Crispr And Cas Genes Market: Product & Service Movement Analysis
  • 6.2 By Product
    • 6.2.1 Global Crispr And Cas Genes Products Market, 2016 - 2027 (USD Million)
    • 6.2.2 Kits & Enzymes
    • 6.2.3 Global Crispr And Cas Genes Kits And Enzymes Market, 2016 - 2027 (USD Million)
      • 6.2.3.1 Vector - Based Cas9
      • 6.2.3.1.1 Global Vector - Based Cas9 Market, 2016 - 2027 (USD Million)
      • 6.2.3.2 Dna - Free Cas9
      • 6.2.3.2.1 Global Dna - Free Cas9 Market, 2016 - 2027 (USD Million)
    • 6.2.4 Libraries
      • 6.2.4.1 Global Crispr And Cas Genes Libraries Market, 2016 - 2027 (USD Million)
    • 6.2.5 Design Tools
      • 6.2.5.1 Global Crispr And Cas Genes Design Tool Market, 2016 - 2027 (USD Million)
    • 6.2.6 Antibodies
      • 6.2.6.1 Global Crispr And Cas Genes Antibodies Market, 2016 - 2027 (USD Million)
    • 6.2.7 Others
      • 6.2.7.1 Global Crispr And Cas Genes Market For Other Products, 2016 - 2027 (USD Million)
  • 6.3 By Service
    • 6.3.1 Global Crispr And Cas Genes Service Market, 2016 - 2027 (USD Million)
    • 6.3.2 Cell Line Engineering
      • 6.3.2.1 Global Cell Engineering Services Market, 2016 - 2027 (USD Million)
    • 6.3.3 Grna Design
      • 6.3.3.1 Global Grna Design Market, 2016 - 2027 (USD Million)
    • 6.3.4 Microbial Gene Editing
      • 6.3.4.1 Global Microbial Gene Editing Market, 2016 - 2027 (USD Million)
    • 6.3.5 Dna Synthesis
      • 6.3.5.1 Global Dna Synthesis Market, 2016 - 2027 (USD Million)

Chapter 7 Application Business Analysis

  • 7.1 Crispr And Cas Genes Market: Application Movement Analysis
  • 7.2 Biomedical
    • 7.2.1 Global Crispr And Cas Genes Market For Biomedical, 2016 - 2027 (USD Million)
    • 7.2.2 Genome Engineering
      • 7.2.2.1 Global Crispr And Cas Genes Market For Genome Engineering, 2016 - 2027 (USD Million)
    • 7.2.3 Disease Model Studies
      • 7.2.3.1 Global Crispr And Cas Genes Market For Disease Model Studies, 2016 - 2027 (USD Million)
    • 7.2.4 Functional Genomics
      • 7.2.4.1 Global Crispr And Cas Genes Market For Functional Genomics, 2016 - 2027 (USD Million)
    • 7.2.5 Epigenetics
      • 7.2.5.1 Global Crispr And Cas Genes Market For Epigenetics, 2016 - 2027 (USD Million)
    • 7.2.6 Others
      • 7.2.6.1 Global Crispr And Cas Genes Market For Other Biomedical Applications, 2016 - 2027 (USD Million)
  • 7.3 Agriculture
    • 7.3.1 Global Crispr And Cas Genes Market For Agriculture, 2016 - 2027 (USD Million)

Chapter 8 End - Use Business Analysis

  • 8.1 Crispr And Cas Genes Market: End - Use Movement Analysis
    • 8.1.1 Biotechnology & Pharmaceutical Companies
      • 8.1.1.1 Global Crispr And Cas Genes Market For Biotechnology & Pharmaceutical Companies, 2016 - 2027 (USD Million)
    • 8.1.2 Academics & Government Research Institutes
      • 8.1.2.1 Global Crispr And Cas Genes Market For Academics & Government Research Institutes, 2016 - 2027 (USD Million)
    • 8.1.3 Contract Research Organizations (Cros)
      • 8.1.3.1 Global Crispr And Cas Genes Market For Cros, 2016 - 2027 (USD Million)

Chapter 9 Regional Business Analysis

  • 9.1 Crispr And Cas Genes Market: Regional Movement Analysis, 2019 And 2027
  • 9.2 North America
    • 9.2.1 North America Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.2.2.2 U.S. Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.2.2.3 U.S. Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.2.3.2 Canada Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.2.3.3 Canada Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
    • 9.3.2 Germany
      • 9.3.2.1 Germany Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.3.2.2 Germany Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.3.2.3 Germany Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.3.3 U.K.
      • 9.3.3.1 U.K. Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.3.3.2 U.K. Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.3.3.3 U.K. Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.3.4 France
      • 9.3.4.1 France Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.3.4.2 France Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.3.4.3 France Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.3.5 Itlay
      • 9.3.5.1 Italy Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.3.5.2 Italy Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.3.5.3 Italy Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.3.6 Spain
      • 9.3.6.1 Spain Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.3.6.2 Spain Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.3.6.3 Spain Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.4.2.2 Japan Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.4.2.3 Japan Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.4.3.2 China Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.4.3.3 China Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.4.4 South Korea
      • 9.4.4.1 South Korea Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.4.4.2 South Korea Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.4.4.3 South Korea Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.5.2.2 Brazil Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.5.2.3 Brazil Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.5.3 Mexico
      • 9.5.3.1 Mexico Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.5.3.2 Mexico Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.5.3.3 Mexico Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
  • 9.6 Middle East & Africa (Mea)
    • 9.6.1 Mea Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.6.2.2 South Africa Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.6.2.3 South Africa Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Saudi Arabia Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
      • 9.6.3.2 Saudi Arabia Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
      • 9.6.3.3 Saudi Arabia Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Top Crispr Innovators And Their Research Focus
  • 10.2 Strategy Framework
  • 10.3 Market Participant Categorization
  • 10.4 Company Profiles
    • 10.4.1 Astrazeneca
      • 10.4.1.1 Company Overview
      • 10.4.1.2 Financial Performance
      • 10.4.1.3 Product Benchmarking
      • 10.4.1.4 Strategic Initiatives
    • 10.4.2 Addgene
      • 10.4.2.1 Company Overview
      • 10.4.2.2 Financial Performance
      • 10.4.2.3 Product Benchmarking
    • 10.4.3 Caribou Biosciences, Inc.
      • 10.4.3.1 Company Overview
      • 10.4.3.2 Financial Performance
      • 10.4.3.3 Product Benchmarking
      • 10.4.3.4 Strategic Initiatives
    • 10.4.4 Cellectis
      • 10.4.4.1 Company Overview
      • 10.4.4.2 Calyxt, Inc.
      • 10.4.4.2.1 Company Overview
      • 10.4.4.3 Financial Performance
      • 10.4.4.3.1 Financial Performance (Calyxt, Inc.)
      • 10.4.4.4 Product Benchmarking
      • 10.4.4.5 Strategic Initiatives
    • 10.4.5 Crispr Therapeutics
      • 10.4.5.1 Company Overview
      • 10.4.5.2 Financial Performance
      • 10.4.5.3 Product Benchmarking
      • 10.4.5.4 Strategic Initiatives
    • 10.4.6 Editas Medicine, Inc.
      • 10.4.6.1 Company Overview
      • 10.4.6.2 Financial Performance
      • 10.4.6.3 Product Benchmarking
      • 10.4.6.4 Strategic Initiatives
    • 10.4.7 Egenesis
      • 10.4.7.1 Company Overview
      • 10.4.7.2 Financial Performance
      • 10.4.7.3 Product Benchmarking
      • 10.4.7.4 Strategic Initiatives
    • 10.4.8 F. Hoffmann - La Roche Ltd.
      • 10.4.8.1 Company Overview
      • 10.4.8.2 Mirus Bio Llc
      • 10.4.8.2.1 Company Overview
      • 10.4.8.3 Financial Performance
      • 10.4.8.3.1 Financial Performance (Mirus Bio Llc)
      • 10.4.8.4 Product Benchmarking
    • 10.4.9 Horizon Discovery Group Plc
      • 10.4.9.1 Company Overview
      • 10.4.9.2 Dharmacon, Inc.
      • 10.4.9.2.1 Company Overview
      • 10.4.9.3 Financial Performance
      • 10.4.9.4 Product Benchmarking
      • 10.4.9.5 Strategic Initiatives
    • 10.4.10 Genscript
      • 10.4.10.1 Company Overview
      • 10.4.10.2 Financial Performance
      • 10.4.10.3 Product Benchmarking
      • 10.4.10.4 Strategic Initiatives
    • 10.4.11 Danaher Corporation
      • 10.4.11.1 Company Overview
      • 10.4.11.2 Integrated Dna Technologies, Inc.
      • 10.4.11.2.1 Company Overview
      • 10.4.11.3 Financial Performance
      • 10.4.11.3.1 Financial Performance (Integrated Dna Technologies, Inc.)
      • 10.4.11.4 Product Benchmarking
      • 10.4.11.5 Strategic Initiatives
    • 10.4.12 Intellia Therapeutics, Inc.
      • 10.4.12.1 Company Overview
      • 10.4.12.2 Financial Performance
      • 10.4.12.3 Product Benchmarking
      • 10.4.12.4 Strategic Initiatives
    • 10.4.13 Lonza
      • 10.4.13.1 Company Overview
      • 10.4.13.2 Financial Performance
      • 10.4.13.3 Product Benchmarking
      • 10.4.13.4 Strategic Initiatives
    • 10.4.14 Merck Kgaa
      • 10.4.14.1 Company Overview
      • 10.4.14.2 Sigma - Aldrich Co. Llc
      • 10.4.14.2.1 Company Overview
      • 10.4.14.3 Financial Performance
      • 10.4.14.4 Product Benchmarking
      • 10.4.14.5 Strategic Initiatives
    • 10.4.15 New England Biolabs
      • 10.4.15.1 Company Overview
      • 10.4.15.2 Financial Performance
      • 10.4.15.3 Product Benchmarking
      • 10.4.15.4 Strategic Initiatives
    • 10.4.16 Takara Bio, Inc.
      • 10.4.16.1 Company Overview
      • 10.4.16.2 Financial Performance
      • 10.4.16.3 Product Benchmarking
      • 10.4.16.4 Strategic Initiatives
    • 10.4.17 Thermo Fisher Scientific, Inc.
      • 10.4.17.1 Company Overview
      • 10.4.17.2 Financial Performance
      • 10.4.17.3 Product Benchmarking
      • 10.4.17.4 Strategic Initiatives
    • 10.4.18 Synthego
      • 10.4.18.1 Company Overview
      • 10.4.18.2 Financial Performance
      • 10.4.18.3 Product Benchmarking
      • 10.4.18.4 Strategic Initiatives
    • 10.4.19 Mammoth Biosciences
      • 10.4.19.1 Company Overview
      • 10.4.19.2 Financial Performance
      • 10.4.19.3 Product Benchmarking
      • 10.4.19.4 Strategic Initiatives
    • 10.4.20 Inscripta, Inc.
      • 10.4.20.1 Company Overview
      • 10.4.20.2 Financial Performance
      • 10.4.20.3 Product Benchmarking
      • 10.4.20.4 Strategic Initiatives
    • 10.4.21 Cibus
      • 10.4.21.1 Company Overview
      • 10.4.21.2 Financial Performance
      • 10.4.21.3 Product Benchmarking
      • 10.4.21.4 Strategic Initiatives
    • 10.4.22 Beam Therapeutics
      • 10.4.22.1 Company Overview
      • 10.4.22.2 Financial Performance
      • 10.4.22.3 Product Benchmarking
      • 10.4.22.4 Strategic Initiatives
    • 10.4.23 Plantedit
      • 10.4.23.1 Company Overview
      • 10.4.23.2 Product Benchmarking
      • 10.4.23.3 Strategic Initiatives
    • 10.4.24 Vertex Pharmaceuticals Incorporated
      • 10.4.24.1 Company Overview
      • 10.4.24.2 Financial Performance
      • 10.4.24.3 Product Benchmarking
      • 10.4.24.4 Strategic Initiatives
    • 10.4.25 Hera Biolabs
      • 10.4.25.1 Company Overview
      • 10.4.25.2 Product Benchmarking
      • 10.4.25.3 Strategic Initiatives
    • 10.4.26 Origene Technologies, Inc.
      • 10.4.26.1 Company Overview
      • 10.4.26.2 Financial Performance
      • 10.4.26.3 Product Benchmarking
      • 10.4.26.4 Strategic Initiatives
    • 10.4.27 Recombinetics, Inc.
      • 10.4.27.1 Company Overview
      • 10.4.27.2 Financial Performance
      • 10.4.27.3 Product Benchmarking
      • 10.4.27.4 Strategic Initiatives

List of Tables

  • TABLE 1 CRISPR - modified crops expected to be launched in the future
  • TABLE 2 Key collaborations between pharmaceutical and gene editing companies
  • TABLE 3 Key partnerships between pharmaceutical and gene editing companies
  • TABLE 4 Variations in the CRISPR system
  • TABLE 5 Methods to check genome editing on - target efficiency
  • TABLE 6 Unbiased methods to analyze off - target effects
  • TABLE 7 Collaboration between CAR - T companies & gene editing companies
  • TABLE 8 Comparison of natural Cas9 and Cas - like variants
  • TABLE 9 Pipeline analysis for Editas Medicine
  • TABLE 10 Pipeline analysis for Intellia Therapeutics, Inc.
  • TABLE 11 Pipeline analysis for CRISPR Therapeutics
  • TABLE 12 Pipeline analysis for Caribou Biosciences, Inc.
  • TABLE 13 Pipeline analysis for eGenesis
  • TABLE 14 Pipeline analysis for Beam Therapeutics
  • TABLE 15 Pipeline analysis for KSQ Therapeutics
  • TABLE 16 Pipeline analysis for Cibus
  • TABLE 17 Types of CRISPR screening libraries
  • TABLE 18 Types of CRISPR controls
  • TABLE 19 Types of cell engineering services
  • TABLE 20 North America CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 21 North America CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 22 North America CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 23 North America CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 24 North America CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 25 North America CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 26 North America CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 27 U.S. CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 28 U.S. CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 29 U.S. CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 30 U.S. CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 31 U.S. CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 32 U.S. CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 33 U.S. CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 34 Canada CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 35 Canada CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 36 Canada CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 37 Canada CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 38 Canada CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 39 Canada CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 40 Canada CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 41 Europe CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 42 Europe CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 43 Europe CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 44 Europe CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 45 Europe CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 46 Europe CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 47 Europe CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 48 Germany CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 49 Germany CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 50 Germany CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 51 Germany CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 52 Germany CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 53 Germany CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 54 Germany CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 55 U.K. CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 56 U.K. CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 57 U.K. CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 58 U.K. CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 59 U.K. CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 60 U.K. CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 61 U.K. CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 62 France CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 63 France CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 64 France CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 65 France CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 66 France CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 67 France CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 68 France CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 69 Italy CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 70 Italy CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 71 Italy CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 72 Italy CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 73 Italy CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 74 Italy CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 75 Italy CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 76 Spain CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 77 Spain CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 78 Spain CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 79 Spain CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 80 Spain CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 81 Spain CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 82 Spain CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 83 Asia Pacific CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 84 Asia Pacific CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 85 Asia Pacific CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 86 Asia Pacific CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 87 Asia Pacific CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 88 Asia Pacific CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 89 Asia Pacific CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 90 Japan CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 91 Japan CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 92 Japan CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 93 Japan CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 94 Japan CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 95 Japan CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 96 Japan CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 97 China CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 98 China CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 99 China CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 100 China CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 101 China CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 102 China CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 103 China CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 104 South Korea CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 105 South Korea CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 106 South Korea CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 107 South Korea CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 108 South Korea CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 109 South Korea CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 110 South Korea CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 111 Latin America CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 112 Latin America CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 113 Latin America CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 114 Latin America CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 115 Latin America CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 116 Latin America CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 117 Latin America CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 118 Brazil CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 119 Brazil CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 120 Brazil CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 121 Brazil CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 122 Brazil CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 123 Brazil CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 124 Brazil CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 125 Mexico CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 126 Mexico CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 127 Mexico CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 128 Mexico CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 129 Mexico CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 130 Mexico CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 131 Mexico CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 132 MEA CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 133 MEA CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 134 MEA CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 135 MEA CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 136 MEA CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 137 MEA CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 138 MEA CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 139 South Africa CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 140 South Africa CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 141 South Africa CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 142 South Africa CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 143 South Africa CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 144 South Africa CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 145 South Africa CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)
  • TABLE 146 Saudi Arabia CRISPR and Cas genes market, by product & service, 2016 - 2027 (USD Million)
  • TABLE 147 Saudi Arabia CRISPR and Cas genes products market, by type, 2016 - 2027 (USD Million)
  • TABLE 148 Saudi Arabia CRISPR and Cas genes kits & enzymes market, by type, 2016 - 2027 (USD Million)
  • TABLE 149 Saudi Arabia CRISPR and Cas genes service market, by type, 2016 - 2027 (USD Million)
  • TABLE 150 Saudi Arabia CRISPR and Cas genes market, by application, 2016 - 2027 (USD Million)
  • TABLE 151 Saudi Arabia CRISPR and Cas genes biomedical applications market, by type, 2016 - 2027 (USD Million)
  • TABLE 152 Saudi Arabia CRISPR and Cas genes market, by end - use, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Industry pyramid analysis
  • Fig. 4 Industry pyramid analysis
  • Fig. 5 Market research approaches
  • Fig. 6 Value - chain - based sizing & forecasting
  • Fig. 7 Industry pyramid analysis
  • Fig. 8 Industry pyramid analysis
  • Fig. 9 Market model for CRISPR and Cas market
  • Fig. 10 Penetration of various technologies in the genome editing market
  • Fig. 11 QFD modeling for market share assessment, for product and service segment
  • Fig. 12 Analysis for the adoption and usage of products for CRISPR and Cas genes
  • Fig. 13 CRISPR studies for plant genome editing, by region
  • Fig. 14 CRISPR crops in the pipeline
  • Fig. 15 Survey respondents on the number of clones screened for identification of cells with desired edits
  • Fig. 16 Regional analysis for CRISPR patents
  • Fig. 17 Regional analysis for CRISPR clinical trials
  • Fig. 18 Regional analysis for CRISPR publications
  • Fig. 19 Multivariable analysis for the regional penetration of CRISPR and Cas genes
  • Fig. 20 Market snapshot, 2019, (USD Million)
  • Fig. 21 Market trends & outlook
  • Fig. 22 CRISPR and Cas genes market segmentation
  • Fig. 23 CRISPR - related patents growth trend, U.S.
  • Fig. 24 Worldwide growth in CRISPR - related patents families
  • Fig. 25 Diversification of patent applications for CRISPR, by end use, as of 2020
  • Fig. 26 Diversification of patent applications as per the CRISPR - enzymes, as of 2020
  • Fig. 27 Penetration and growth prospect mapping, by biomedical applications, 2019
  • Fig. 28 Comparison among prototype genome - editing techniques
  • Fig. 29 Consumer awareness of personalized medicine
  • Fig. 30 Technology penetration in CRISPR genome editing
  • Fig. 31 CRISPR and Cas genes market driver impact
  • Fig. 32 CRISPR and Cas genes market restraint impact
  • Fig. 33 Side effects of GM foods
  • Fig. 34 Key public players analysis
  • Fig. 35 Key private players analysis
  • Fig. 36 Types of major deals & strategic alliances
  • Fig. 37 CRISPR Therapeutics: Partnerships & alliances analysis
  • Fig. 38 Market entry strategies for small and mid - sized biopharma companies (End user of gene editing technologies) and CRISPR technology developers
  • Fig. 39 CRISPR Therapeutics: Translation
  • Fig. 40 CRISPR gene editing companies' toolboxes
  • Fig. 41 Clinical strategy of operating companies
  • Fig. 42 CRISPR and Cas genes market: Product & service outlook and key takeaways
  • Fig. 43 CRISPR and Cas genes market: Product & service movement analysis
  • Fig. 44 Global CRISPR and Cas genes products market, 2016 - 2027 (USD Million)
  • Fig. 45 Global CRISPR and Cas genes kits and enzymes market, 2016 - 2027 (USD Million)
  • Fig. 46 Global vector - based Cas9 market, 2016 - 2027 (USD Million)
  • Fig. 47 Global DNA - free Cas9 market, 2016 - 2027 (USD Million)
  • Fig. 48 Global CRISPR and Cas genes libraries market, 2016 - 2027 (USD Million)
  • Fig. 49 Global CRISPR and Cas genes design tool market, 2016 - 2027 (USD Million)
  • Fig. 50 Applications of CRISPR - Cas9 antibodies
  • Fig. 51 Global CRISPR and Cas genes antibodies market, 2016 - 2027 (USD Million)
  • Fig. 52 Global CRISPR and Cas genes market for other products, 2016 - 2027 (USD Million)
  • Fig. 53 Global CRISPR and Cas genes service market, 2016 - 2027 (USD Million)
  • Fig. 54 Global cell engineering services market, 2016 - 2027 (USD Million)
  • Fig. 55 Global gRNA design market, 2016 - 2027 (USD Million)
  • Fig. 56 Global microbial gene editing market, 2016 - 2027 (USD Million)
  • Fig. 57 Global DNA synthesis market, 2016 - 2027 (USD Million)
  • Fig. 58 CRISPR and Cas genes market: Application outlook and key takeaways
  • Fig. 59 Potential applications of CRISPR technology for biomedical diagnostics
  • Fig. 60 CRISPR and Cas genes market: Application movement analysis
  • Fig. 61 Global CRISPR and Cas genes market for biomedical, 2016 - 2027 (USD Million)
  • Fig. 62 Global CRISPR and Cas genes market for genome engineering, 2016 - 2027 (USD Million)
  • Fig. 63 Global CRISPR and Cas genes market for disease model studies, 2016 - 2027 (USD Million)
  • Fig. 64 Global CRISPR and Cas genes market for functional genomics, 2016 - 2027 (USD Million)
  • Fig. 65 Global CRISPR and Cas genes market for epigenetics, 2016 - 2027 (USD Million)
  • Fig. 66 Global CRISPR and Cas genes market for other biomedical applications, 2016 - 2027 (USD Million)
  • Fig. 67 Global CRISPR and Cas genes market for agriculture, 2016 - 2027 (USD Million)
  • Fig. 68 CRISPR and Cas genes market: End - use outlook and key takeaways
  • Fig. 69 CRISPR and Cas genes market: End - use movement analysis
  • Fig. 70 Global CRISPR and Cas genes market for biotechnology & pharmaceutical companies, 2016 - 2027 (USD Million)
  • Fig. 71 Global CRISPR and Cas genes market for academics & government research institutes, 2016 - 2027 (USD Million)
  • Fig. 72 Global CRISPR and Cas genes market for CROs, 2016 - 2027 (USD Million)
  • Fig. 73 CRISPR and Cas genes market: Regional outlook and key takeaways
  • Fig. 74 CRISPR and Cas genes market: Regional movement analysis
  • Fig. 75 North America
  • Fig. 76 North America CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 77 U.S.
  • Fig. 78 U.S. CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 79 Canada
  • Fig. 80 Canada CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 81 Europe
  • Fig. 82 Europe CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 83 Germany
  • Fig. 84 Germany CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 85 U.K.
  • Fig. 86 U.K. CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 87 France
  • Fig. 88 France CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 89 Italy
  • Fig. 90 Italy CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 91 Spain
  • Fig. 92 Spain CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 93 Asia Pacific
  • Fig. 94 Asia Pacific CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 95 Japan
  • Fig. 96 Japan CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 97 China
  • Fig. 98 China CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 99 South Korea
  • Fig. 100 South Korea CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 101 Latin America
  • Fig. 102 Latin America CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 103 Brazil
  • Fig. 104 Brazil CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 105 Mexico
  • Fig. 106 Mexico CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 107 MEA
  • Fig. 108 MEA CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 109 South Africa
  • Fig. 110 South Africa CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 111 Saudi Arabia
  • Fig. 112 Saudi Arabia CRISPR and Cas genes market estimates and forecast, 2016 - 2027 (USD Million)
  • Fig. 113 Top CRISPR innovators and their research focus
  • Fig. 114 Strategy framework
  • Fig. 115 Market participant categorization